JP2020535119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535119A5 JP2020535119A5 JP2020513721A JP2020513721A JP2020535119A5 JP 2020535119 A5 JP2020535119 A5 JP 2020535119A5 JP 2020513721 A JP2020513721 A JP 2020513721A JP 2020513721 A JP2020513721 A JP 2020513721A JP 2020535119 A5 JP2020535119 A5 JP 2020535119A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- determined
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 41
- 230000035772 mutation Effects 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 239000003550 marker Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 20
- 230000014509 gene expression Effects 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 8
- 201000002528 pancreatic cancer Diseases 0.000 claims 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 6
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- -1 CD86 Proteins 0.000 claims 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 5
- 102100033499 Interleukin-34 Human genes 0.000 claims 5
- 101710181549 Interleukin-34 Proteins 0.000 claims 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 4
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 4
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 4
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 4
- 102100030386 Granzyme A Human genes 0.000 claims 4
- 102100038393 Granzyme H Human genes 0.000 claims 4
- 102100022087 Granzyme M Human genes 0.000 claims 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 4
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 4
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 4
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 4
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 4
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 4
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 4
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 4
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims 4
- 101000900697 Homo sapiens Granzyme M Proteins 0.000 claims 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 4
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 claims 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 4
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 claims 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 4
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 claims 4
- 101000946833 Homo sapiens T-cell surface glycoprotein CD8 beta chain Proteins 0.000 claims 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 4
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 4
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 102100023370 Protein NKG7 Human genes 0.000 claims 4
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 4
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 4
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 claims 4
- 102100034928 T-cell surface glycoprotein CD8 beta chain Human genes 0.000 claims 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 4
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 210000001616 monocyte Anatomy 0.000 claims 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 102100021186 Granulysin Human genes 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 3
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 3
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 3
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 3
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims 3
- 102100028467 Perforin-1 Human genes 0.000 claims 3
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims 3
- 102100030766 Apolipoprotein L3 Human genes 0.000 claims 2
- 102100026658 Cathepsin W Human genes 0.000 claims 2
- 101000793443 Homo sapiens Apolipoprotein L3 Proteins 0.000 claims 2
- 101000910988 Homo sapiens Cathepsin W Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 108091092878 Microsatellite Proteins 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 239000002771 cell marker Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000011272 standard treatment Methods 0.000 claims 2
- 238000011222 transcriptome analysis Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 claims 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 102100025136 Macrosialin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 238000003559 RNA-seq method Methods 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060052A JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558161P | 2017-09-13 | 2017-09-13 | |
| US62/558,161 | 2017-09-13 | ||
| US201762580154P | 2017-11-01 | 2017-11-01 | |
| US62/580,154 | 2017-11-01 | ||
| US201762581962P | 2017-11-06 | 2017-11-06 | |
| US62/581,962 | 2017-11-06 | ||
| US201862671887P | 2018-05-15 | 2018-05-15 | |
| US62/671,887 | 2018-05-15 | ||
| US201862679612P | 2018-06-01 | 2018-06-01 | |
| US62/679,612 | 2018-06-01 | ||
| PCT/US2018/050711 WO2019055537A1 (en) | 2017-09-13 | 2018-09-12 | ANTI-CSF1R AND ANTI-PD -1 ANTIBODY POLYTHERAPY FOR PANCREATIC CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060052A Division JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535119A JP2020535119A (ja) | 2020-12-03 |
| JP2020535119A5 true JP2020535119A5 (cg-RX-API-DMAC7.html) | 2021-10-21 |
Family
ID=63708492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513721A Pending JP2020535119A (ja) | 2017-09-13 | 2018-09-12 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法 |
| JP2023060052A Pending JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060052A Pending JP2023093514A (ja) | 2017-09-13 | 2023-04-03 | 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ－１抗体組合せ併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11421034B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3681535A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020535119A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200051024A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111479586A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018334171A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020004879A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073531A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272669A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020002301A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202001606XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019055537A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114127315A (zh) * | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| CN114502241A (zh) * | 2019-08-01 | 2022-05-13 | 纽约大学 | 抗半乳凝素-9抗体和化疗剂的联合癌症疗法 |
| KR20210100457A (ko) * | 2020-02-06 | 2021-08-17 | 아주대학교산학협력단 | 케모카인 억제제, 콜로니 자극 인자 억제제 및 면역항암제를 포함하는 암의 예방 또는 치료용 조성물 및 병용 요법 |
| US20230184771A1 (en) * | 2020-04-21 | 2023-06-15 | Board Of Regents, The University Of Texas System | Methods for treating bladder cancer |
| EP4112746A1 (en) * | 2021-07-02 | 2023-01-04 | STRATIFYER Molecular Pathology GmbH | Method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2518911B2 (ja) | 1987-10-23 | 1996-07-31 | 森永乳業株式会社 | ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5866114A (en) | 1992-06-09 | 1999-02-02 | Chiron Corporation | Crystallization of M-CSFα |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| PT1223980E (pt) | 1999-10-28 | 2003-10-31 | Reinhold Hofbauer | Utilizacao de inibidores de csf-1 |
| WO2001034177A2 (en) | 1999-11-08 | 2001-05-17 | The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| SI1638941T1 (sl) | 2003-05-22 | 2010-11-30 | Abbott Lab | Inhibitorji indazol benzizoksazol in benzizotiazol kinaze |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| JP2007524671A (ja) | 2004-01-21 | 2007-08-30 | カイロン コーポレイション | Ｍ−ｃｓｆムテインおよびその使用 |
| CA2565974A1 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| EP1778842B8 (en) | 2004-07-22 | 2012-03-21 | Five Prime Therapeutics, Inc. | Compositions and methods of use for mgd-csf in disease treatment |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006320858A1 (en) | 2005-11-10 | 2007-06-07 | Receptor Biologix, Inc. | Methods for production of receptor and ligand isoforms |
| WO2007075933A2 (en) | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| EP1977238B1 (en) | 2005-12-22 | 2016-09-28 | Novartis AG | Soluble human m-csf receptor and uses thereof |
| WO2007081879A2 (en) | 2006-01-05 | 2007-07-19 | Novartis Ag | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2008060610A2 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| ATE494306T1 (de) | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| WO2008150383A1 (en) | 2007-05-30 | 2008-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | Csf-1r mutants |
| SG10201500328QA (en) | 2007-08-21 | 2015-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| AU2008318656A1 (en) | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to FMS treatment |
| EP2241333A1 (en) | 2007-12-12 | 2010-10-20 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
| RU2547586C2 (ru) | 2008-03-14 | 2015-04-10 | Трансжене С.А. | Антитело против csf-1r |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| WO2010001617A1 (en) | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| HUE026201T2 (en) | 2009-12-10 | 2016-05-30 | Hoffmann La Roche | Antibodies binding to human CSF1R extracellular domain 4 and their use |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| CA2797399C (en) | 2010-05-04 | 2021-03-02 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| WO2012062218A1 (en) | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| WO2012082573A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| EP2768861A1 (en) | 2011-10-21 | 2014-08-27 | Institut National de la Sante et de la Recherche Medicale (INSERM) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
| CA2851771C (en) | 2011-10-21 | 2018-09-11 | Transgene Sa | Modulation of macrophage activation |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| RU2718751C2 (ru) | 2012-08-31 | 2020-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r) |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| PH12020550847A1 (en) * | 2014-02-04 | 2022-05-11 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| HRP20210440T1 (hr) * | 2014-10-29 | 2021-04-30 | Five Prime Therapeutics, Inc. | Kombinirana terapija za rak |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| KR102804118B1 (ko) * | 2016-10-06 | 2025-05-09 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| KR20240006698A (ko) * | 2017-07-21 | 2024-01-15 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
-
2018
- 2018-09-12 JP JP2020513721A patent/JP2020535119A/ja active Pending
- 2018-09-12 CA CA3073531A patent/CA3073531A1/en active Pending
- 2018-09-12 US US16/646,690 patent/US11421034B2/en active Active
- 2018-09-12 BR BR112020004879-8A patent/BR112020004879A2/pt not_active IP Right Cessation
- 2018-09-12 AU AU2018334171A patent/AU2018334171A1/en not_active Abandoned
- 2018-09-12 MX MX2020002301A patent/MX2020002301A/es unknown
- 2018-09-12 KR KR1020207010187A patent/KR20200051024A/ko not_active Ceased
- 2018-09-12 SG SG11202001606XA patent/SG11202001606XA/en unknown
- 2018-09-12 CN CN201880058749.8A patent/CN111479586A/zh active Pending
- 2018-09-12 EP EP18779538.0A patent/EP3681535A1/en not_active Withdrawn
- 2018-09-12 WO PCT/US2018/050711 patent/WO2019055537A1/en not_active Ceased
-
2020
- 2020-02-13 IL IL272669A patent/IL272669A/en unknown
-
2022
- 2022-07-14 US US17/812,592 patent/US20230192870A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060052A patent/JP2023093514A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11913075B2 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
| JP2020535119A5 (cg-RX-API-DMAC7.html) | ||
| US20210371932A1 (en) | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients | |
| Lecerf et al. | Immune gene expression in head and neck squamous cell carcinoma patients | |
| US20210071255A1 (en) | Methods for identification of genes and genetic variants for complex phenotypes using single cell atlases and uses of the genes and variants thereof | |
| US11326211B2 (en) | Blood-based biomarkers of tumor sensitivity to PD-1 antagonists | |
| US20200347456A1 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
| KR102667593B1 (ko) | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 | |
| JP7197556B2 (ja) | がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法 | |
| US10711312B2 (en) | Methods for immunotherapy-based treatment and assessment of cancer | |
| Fasano et al. | Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer | |
| Davar et al. | Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial | |
| KR20190112027A (ko) | 암 면역요법의 임상 효과 예측을 위한 면역 바이오마커 | |
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| US20210395374A1 (en) | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | |
| JP2020524149A5 (cg-RX-API-DMAC7.html) | ||
| US10406218B2 (en) | Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of Mycobacterium tuberculosis | |
| WO2019147681A1 (en) | Methods for predicting tumor response to immunotherapy | |
| Yao et al. | Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment | |
| JP2022179694A (ja) | Ｋｒａｓバリアントがん患者の免疫ベースの処置 | |
| Aoki et al. | Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade | |
| Jang et al. | RNA N6‐Methyladenosine‐Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN‐γ Signaling in Gastric Cancer | |
| JP7739269B2 (ja) | がん療法のための複合バイオマーカー | |
| EP3976832A1 (en) | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy | |
| Qi et al. | The co-inhibitory immune checkpoint proteins B7-H1 (PD-L1) and B7-H4 in high grade glioma: from bench to bedside |